UPLIFT (ENGOT-OV67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer

被引：0

作者：

Richardson, Debra ^{[1
]}

Concin, Nicole ^{[2
]}

Hays, John ^{[3
]}

Perez Fidalgo, Jose Alejandro ^{[4
]}

Pothuri, Bhavana ^{[5
]}

Banerjee, Susana ^{[6
]}

Ghamande, Sharad ^{[7
]}

Ray Coquard, Isabelle ^{[8
]}

Germanova, Anna ^{[9
]}

Rimel, Bobbie ^{[10
]}

Lorusso, Domenica ^{[11
]}

Cloven, Noelle ^{[12
]}

Baurain, Jean-Francois ^{[13
]}

Randall, Leslie ^{[14
]}

Brasiuniene, Birute ^{[15
]}

Tseng, Jill ^{[16
]}

Klasa-Mazurkiewicz, Dagmara ^{[17
]}

Werner, Theresa ^{[18
]}

Oaknin, Ana ^{[19
]}

Ang, Joo Ern ^{[20
]}

Leary, Alexandra ^{[21
]}

Bishop, Erin ^{[22
]}

Marth, Christian ^{[23
]}

Bradshaw, Chelsea ^{[24
]}

Burger, Robert ^{[24
]}

Gonzalez Martin, Antonio Jose ^{[25
]}

机构：

[1] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA

[2] Evangelische Kliniken Essen Mitte, Essen, Germany

[3] Ohio State Univ, Columbus, OH USA

[4] Hosp Clin Univ Valencia, Valencia, Spain

[5] New York Unviers, Langone Hlth, New York, NY USA

[6] Royal Marsden NHS, NCRI, London, England

[7] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

[8] Ctr Leon Berard, Lyon, France

[9] Charles Univ Prague, Prague, Czech Republic

[10] Cedars Sinai Med Ctr, Los Angeles, CA USA

[11] Fdn Policlin Univ Gemelli IRCCS, Rome, Italy

[12] Texas Oncol Ft Worth Canc Ctr, Ft Worth, TX USA

[13] Clin Univ St Luc, Brussels, Belgium

[14] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA

[15] Vilnius Univ, Natl Canc Inst Lithuania, Vilnius, Lithuania

[16] Univ Calif Irvine, Irvine, CA USA

[17] Med Univ Gdansk, Gdansk, Poland

[18] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[19] Vall Hebron Hosp Univ, Barcelona, Spain

[20] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[21] Inst Cancerol Gustave Roussy, Villejuif, France

[22] Med Coll Wisconsin, Milwaukee, WI USA

[23] Med Univ Innsbruck, Innsbruck, Austria

[24] Mersana Therapeut, Cambridge, MA USA

[25] Univ Navarra, Madrid, Spain

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 190卷

关键词：

D O I：

10.1016/j.ygyno.2024.07.085

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

13 [LBA]

引用

页码：S56 / S56

页数：1

共 23 条

[1] UPLIFT (ENGOT-OV67/GOG-3048) A PIVOTAL COHORT OF THE XMT-1536-1 TRIAL OF UPIFITAMAB RILSODOTIN (XMT-1536; UPRI), A NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) IN PLATINUM-RESISTANT OVARIAN CANCER
Richardson, Debra
Perez Fidalgo, Jose Alejandro
Gonzalez-Martin, Antonio
Oaknin, Ana
Hamilton, Erika
Hays, John
Pothuri, Bhavana
Papadopoulos, Kyriakos
Taylor, Sara
Huang, Marilyn
Lee, Yeh-Chen
Krivak, Thomas
Moreno-Garcia, Victor
Calvo, Emiliano
Randall, Leslie
Starks, David
Ross, Malcom
Duska, Linda
Gao, Bo
Poka, Robert
Putiri, Emily
Barrett, Jamie
Demars, Leslie
Concin, Nicole
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A241 - A241
[2] UPLIFT (ENGOT-ov67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin, a NaPi2b-directed dolaflexin antibody-drug conjugate, in platinum-resistant ovarian cancer
Richardson, Debra
Iyer, Gopa
Schmid, Anita
Palma, Norma
Navarro, Willis
Ahnert, Jordi Rodon
GYNECOLOGIC ONCOLOGY, 2024, 190 : S285 - S286
[3] UPLIFT (ENGOT-OV67/GOG-3048) A PIVOTAL COHORT OF UPIFITAMAB RILSODOTIN, A NAPI2B-DIRECTED ADC IN PLATINUM-RESISTANT OVARIAN CANCER
Concin, N.
Hamilton, E.
Randall, L. M.
Banerjee, S.
Mileshkin, L.
Coleman, R. L.
Monk, B.
Mirza, M. R.
Savarese, A.
Ray-Coquard, I.
Perez Fidalgo, J. A.
Bernardo, P.
Putiri, E.
Burger, R.
Mosher, R.
Richardson, D.
Cibula, D.
Madry, R.
Chekerov, R.
Van Gorp, T.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A205 - A205
[4] Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.
Richardson, Debra L.
Hamilton, Erika P.
Oaknin, Ana
Randall, Leslie M.
Banerjee, Susana N.
Taylor, Sara Kristina
Mileshkin, Linda R.
Coleman, Robert L.
Monk, Bradley J.
Mirza, Mansoor Raza
Bernardo, Patricia
Mosher, Rebecca
Jansen, Valerie Malyvanh
Savarese, Antonella
Van Gorp, Toon
Madry, Radoslaw
Ray-Coquard, Isabelle Laure
Concin, Nicole
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer
Lakhani, Nehal
Burns, Timothy
Barve, Minal
Edenfield, Jeffery
Hays, John
Zarwan, Corrine
Werner, Theresa
Anderson, Charles
Buscema, Joseph
Bernardo, Patricia
Keeton, Erika
Carrington, Cassandra
Burger, Robert
GYNECOLOGIC ONCOLOGY, 2022, 166 : S285 - S286
[6] Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer
Richardson, Debra
Hamilton, Erika
Barve, Minal
Anderson, Charles
Taylor, Sara
Lakhani, Nehal
Buscema, Joseph
Tolcher, Anthony
Zarwan, Corrine
Werner, Theresa
Hays, John
Arend, Rebecca
Edenfield, Jeffery
Putiri, Emily
Bernardo, Patricia
Burger, Robert
Matulonis, Ursula
GYNECOLOGIC ONCOLOGY, 2022, 166 : S48 - S48
[7] UPGRADE: PHASE 1 COMBINATION TRIAL OF THE NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) UPIFITAMAB RILSODOTIN (UPRI; XMT-1536) IN PATIENTS WITH OVARIAN CANCER
Hays, John
Werner, Theresa
Lakhani, Nehal
Edenfield, Jeffrey
Buscema, Joseph
Burns, Timothy
Carrington, Cassandra
Keeton, Erika
Burger, Robert
Anderson, Charles
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A235 - A235
[8] Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A post-hoc analysis of a phase 1b expansion study in ovarian cancer
Monk, Bradley
Concin, Nicole
Richardson, Debra
Ray-Coquard, Isabelle
Pothuri, Bhavana
Marth, Christian
Bernardo, Patricia
Burger, Robert
Im, Ellie
Aldairy, Wassim
Coleman, Robert
Mirza, Mansoor
GYNECOLOGIC ONCOLOGY, 2022, 166 : S166 - S166
[9] UP-NEXT (GOG-3049/ENGOT-OV71-NSGO-CTU): A STUDY OF UPIFITAMAB RILSODOTIN (UPRI), A NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER
Richardson, Debra
Harter, Philipp
O'Malley, David
Gonzalez-Martin, Antonio
Herzog, Thomas
Rogalski, Caroline
Burger, Robert
Mirza, Mansoor
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A241 - A241
[10] Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
Hamilton, E. P.
Barve, M. A.
Tolcher, A. W.
Buscema, J.
Papadopoulos, K. P.
Zarwan, C.
Anderson, C. K.
Doroshow, D.
Wang, D.
Huebner, D.
Jansen, V. M.
Jarlenski, D.
Mosher, R.
Kaufman, J.
Moore, K. N.
Richardson, D. L.
ANNALS OF ONCOLOGY, 2020, 31 : S627 - S628

← 1 2 3 →